A Serosurvey of Japanese Encephalitis Virus in Monkeys and Humans Living in Proximity in Thailand.

Japanese encephalitis virus (JEV) is a member of the Flaviviridae family and one of Asia's most common causes of encephalitis. JEV is a zoonotic virus that is transmitted to humans through the bite of infected mosquitoes of the Culex species. While humans are dead-end hosts for the virus, domestic animals such as pigs and birds are amplification hosts. Although JEV naturally infected monkeys have been reported in Asia, the role of non-human primates (NHPs) in the JEV transmission cycle has not been intensively investigated. In this study, we demonstrated neutralizing antibodies against JEV in NHPs (Macaca fascicularis) and humans living in proximity in two provinces located in western and eastern Thailand by using Plaque Reduction Neutralization Test (PRNT). We found a 14.7% and 5.6% seropositive rate in monkeys and 43.7% and 45.2% seropositive rate in humans living in west and east Thailand, respectively. This study observed a higher seropositivity rate in the older age group in humans. The presence of JEV neutralizing antibodies in NHPs that live in proximity to humans shows the occurrence of natural JEV infection, suggesting the endemic transmission of this virus in NHPs. According to the One Health concept, regular serological studies should be conducted especially at the animal-human interface.

Seroprevalence of Chikungunya and Zika virus in nonhuman primates: A systematic review and meta-analysis.

Chikungunya virus (CHIKV) and Zika virus (ZIKV) are mosquito-borne viruses that have caused several outbreaks worldwide. Aedes mosquitoes transmit these viruses mainly through sylvatic and urban transmission cycles. In the sylvatic cycle, nonhuman primates (NHPs) can be infected with CHIKV and ZIKV and may play an essential role as reservoirs for virus transmission. To improve our knowledge on the role of NHPs in the sylvatic cycle, we performed a systematic review and meta-analysis study on the seroprevalence of CHIKV and ZIKV worldwide in NHPs. According to the PRISMA guidelines, 17 CHIKV and 16 ZIKV seroprevalence studies in NHPs from 3 online databases: PubMed, Embase, and Scopus were selected. Data were extracted, including location and study year, type of NHP, sample size, serological tests, and seropositivity. All included studies have high-quality scores, between 5 and 8, corresponding to the grading criteria. Seroprevalence estimation was pooled using the 'meta' package in the R statistical software. The estimated pooled seroprevalence of CHIKV and ZIKV in NHP was 17% (95%CI: 5-34, I2: 99%, p < 0.05) and 6% (95% CI: 2-12, I 2 : 92%, p < 0.05), respectively. Most of the NHPs tested were wild Old World monkeys. The subgroup was analyzed by continents; high seropositive CHIKV and ZIKV were found in African NHPs at 35% (95% CI 9-66.0, I 2  = 100) and 16% (95% CI 1-44, I 2  = 97), respectively. While NHPs in America have 7% (95% CI 0-28, I 2 = 99) and 2% (95% CI 1-3, I 2 = 54) against CHIKV and ZIKV. In Asia, 6% (95% CI: 5-34, I 2  = 96) CHIKV seroprevalence and 7% (95% CI 0-20, I 2  = 98) ZIKV seroprevalence were found in NHP. This study provides a comprehensive overview of the seroprevalence of CHIKV and ZIKV among NHPs in various regions.

Virological, Serological and Clinical Analysis of Chikungunya Virus Infection in Thai Patients.

From 2018 to 2020, the Chikungunya virus (CHIKV) outbreak re-emerged in Thailand with a record of more than 10,000 cases up until the end of 2020. Here, we studied acute CHIKV-infected patients who had presented to the Bangkok Hospital for Tropical Diseases from 2019 to 2020 by assessing the relationship between viral load, clinical features, and serological profile. The results from our study showed that viral load was significantly high in patients with fever, headache, and arthritis. We also determined the neutralizing antibody titer in response to the viral load in patients, and our data support the evidence that an effective neutralizing antibody response against the virus is important for control of the viral load. Moreover, the phylogenetic analysis revealed that the CHIKV strains we studied belonged to the East, Central, and Southern African (ECSA) genotype, of the Indian ocean lineage (IOL), and possessed E1-K211E and E1-I317V mutations. Thus, this study provides insight for a better understanding of CHIKV pathogenesis in acute infection, along with the genomic diversity of the current CHIKV strains circulating in Thailand.

Determination of T Cell Responses in Thai Systemic Sclerosis Patients.

Objectives: This study is aimed at determining the role of T cells by assessing the numbers of IFN-γ- and IL-2-secreting T cells following stimulation with peptides derived from DNA topoisomerase-I protein in Thai SSc patients. Methods: Fifty Thai SSc patients and 50 healthy controls (HC) joined this study. IFN-γ and IL-2 levels upon stimulation of T cells with 6 peptides derived from DNA topoisomerase-I protein were determined. Anti-nuclear antibodies (ANA) and anti-Scl-70 antibodies were determined by using the ELISA method. Results: In SSc patients, we detected a significantly higher number of IFN-γ- and IL-2-secreting CD8+ T cells than IFN-γ- and IL-2-secreting CD4+ T cells after stimulation with pooled peptides derived from DNA topoisomerase-I protein. A similar percentage of CD4+IL-2+, CD4+IFN-γ +, and CD8+IL-2+ were detected following stimulation with DNA topoisomerase-I protein -in SSc patients with anti-Scl-70 antibody (SSc/anti-Scl-70+) and those without. In contrast, the amount of CD8+IFN-γ + cells was significantly higher in SSc/anti-Scl-70+ than those without. Stimulation with individual peptides showed that CSLRVEHINLHPELD (sPep3; 15 amino acids; position 505-519 of DNA topoisomerase-I protein) was the optimal epitope that induced T cells secreting the highest levels of IFN-γ and IL-2. A higher percentage of IFN-γ +CD4+ T cells was detected in SSc/anti-Scl-70+ than those without the following stimulation with peptides 2 (amino acid position 475-486 [RAVALYFIDKLA] of protein DNA topoisomerase). Conclusion: The results from this study emphasize the critical role of DNA topoisomerase-I peptides on the activation of T cells in SSc patients. The findings provide a better understanding of SSc's immunopathogenesis and may lead to the development of diagnostic tools and specific treatments for SSc in the future.